)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
4D Molecular Therapeutics
4D Molecular Therapeutics (FDMT) investor relations material
4D Molecular Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary18 Mar, 2026
Executive summary
Completed enrollment in 4FRONT-1 wet AMD Phase 3 trial ahead of schedule; topline data expected H1 2027.
Entered strategic partnership with Otsuka for 4D-150 in Asia-Pacific, receiving $85M upfront and eligibility for up to $336M in milestones.
Expanded leadership team and strengthened financial position with $118M in new financing.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $514M as of December 31, 2025.
Collaboration and license revenue was $85M for 2025, up from $0M in 2024, driven by Otsuka partnership.
R&D expenses rose to $196M in 2025 from $141M in 2024, reflecting increased clinical trial activity.
Net loss narrowed to $140M in 2025 from $161M in 2024.
Net loss per share improved to $(2.42) from $(2.98) year-over-year.
Outlook and guidance
Cash runway expected to fund operations into the second half of 2028.
4D-150 topline Phase 3 data for wet AMD expected H1 2027; Phase 2b data mid-2026.
SPECTRA DME trial 2-year data expected H2 2026; global Phase 3 DME trial to start Q3 2026.
4D-710 CF lung disease program update expected H2 2026.
4FRONT enrollment increase: cost implications
Otsuka partnership: global strategy implications
4D-710 long-term data: market potential
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from 4D Molecular Therapeutics
- 4D-150 delivers paradigm-shifting durability for retinal diseases, reducing treatment burden by up to 92%.FDMT
Corporate presentation18 Mar 2026 - Phase 3 gene therapy trials for retinal diseases are fully enrolled, with data expected in 2027.FDMTBarclays 28th Annual Global Healthcare Conference12 Mar 2026
- 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential.FDMTLeerink Global Healthcare Conference 202610 Mar 2026
- 4D-150 advances in global phase III trials, showing strong safety and reduced treatment burden.FDMTTD Cowen 46th Annual Health Care Conference3 Mar 2026
- 4D-150 cut injections by 89% and left 77% injection-free at 24 weeks with improved vision.FDMTStudy Update3 Feb 2026
- 4D-150 delivers durable efficacy and safety in wet AMD; Phase 3 design due September 2024.FDMTH.C. Wainwright 4th Annual Ophthalmology Virtual Conference2 Feb 2026
- 4D-710 showed robust CFTR expression, clinical benefit, and strong safety, advancing to Phase 2.FDMTStudy Update1 Feb 2026
- Strong clinical progress in ophthalmology and CF, with key catalysts and robust funding ahead.FDMTGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Gene therapy programs advance with strong wet AMD data and promising cystic fibrosis results.FDMTJefferies 2024 Global Healthcare Conference1 Feb 2026
Next 4D Molecular Therapeutics earnings date
Q1 20268 May, 2026
4D Molecular Therapeutics
Next 4D Molecular Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage